Open Access

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers

  • Eleni van Schooneveld1, 2Email author,
  • Maartje CA Wouters3,
  • Ilse Van der Auwera2,
  • Dieter J Peeters2, 4,
  • Hans Wildiers1, 2,
  • Peter A Van Dam2,
  • Ignace Vergote1, 2,
  • Peter B Vermeulen2,
  • Luc Y Dirix2 and
  • Steven J Van Laere1, 2
Contributed equally
Breast Cancer Research201214:R34

DOI: 10.1186/bcr3127

Received: 4 October 2011

Accepted: 21 February 2012

Published: 21 February 2012

Abstract

Introduction

MicroRNAs (miRNAs) are a group of small noncoding RNAs involved in the regulation of gene expression. As such, they regulate a large number of cellular pathways, and deregulation or altered expression of miRNAs is associated with tumorigenesis. In the current study, we evaluated the feasibility and clinical utility of circulating miRNAs as biomarkers for the detection and staging of breast cancer.

Methods

miRNAs were extracted from a set of 84 tissue samples from patients with breast cancer and eight normal tissue samples obtained after breast-reductive surgery. After reverse transcription and preamplification, 768 miRNAs were profiled by using the TaqMan low-density arrays. After data normalization, unsupervised hierarchical cluster analysis (UHCA) was used to investigate global differences in miRNA expression between cancerous and normal samples. With fold-change analysis, the most discriminating miRNAs between both tissue types were selected, and their expression was analyzed on serum samples from 20 healthy volunteers and 75 patients with breast cancer, including 16 patients with untreated metastatic breast cancer. miRNAs were extracted from 200 μl of serum, reverse transcribed, and analyzed in duplicate by using polymerase chain reaction (qRT-PCR).

Results

UHCA showed major differences in miRNA expression between tissue samples from patients with breast cancer and tissue samples from breast-reductive surgery (P < 0.0001). Generally, miRNA expression in cancerous samples tends to be repressed when compared with miRNA expression in healthy controls (P = 0.0685). The four most discriminating miRNAs by fold-change (miR-215, miR-299-5p, miR-411, and miR-452) were selected for further analysis on serum samples. All miRNAs at least tended to be differentially expressed between serum samples from patients with cancer and serum samples from healthy controls (miR-215, P = 0.094; miR-299-5P, P = 0.019; miR-411, P = 0.002; and miR-452, P = 0.092). For all these miRNAs, except for miR-452, the greatest difference in expression was observed between serum samples from healthy volunteers and serum samples from untreated patients with metastatic breast cancer.

Conclusions

Our study provides a basis for the establishment of miRNAs as biomarkers for the detection and eventually staging of breast cancer through blood-borne testing. We identified and tested a set of putative biomarkers of breast cancer and demonstrated that altered levels of these miRNAs in serum from patients with breast cancer are particularly associated with the presence of metastatic disease.

Introduction

MicroRNAs (miRNAs) are a group of small (20 to 25 nt) noncoding RNAs able to regulate gene expression posttranscriptionally by binding to the 3'-untranslated region (UTR) of target mRNAs [13]. Since the initial discovery in Caenorhabditis elegans, more than 1,000 human miRNAs have been described, each of them targeting about 100 different mRNA molecules [46]. In this way, approximately 30% of all human genes are regulated by miRNAs [7, 8], thereby influencing several different pathways and processes in the cell, including development, differentiation, apoptosis, and cell proliferation [911].

As miRNAs are involved in fine-tuning gene expression in the cell [1, 2], deregulation of miRNA expression could lead to altered gene expression, which might contribute to the development of cancer [12]. Several studies have shown a differential miRNA-expression profile in cancer as compared with normal controls [1315]. Although specific miRNAs can be upregulated in cancer [16], global miRNA downregulation is a common trait of human malignancies [13, 17]. Furthermore, miRNAs are involved in the metastatic cascade, which is the most dismal feature of tumor biology with respect to patient prognosis.

MiRNA-expression profiling of primary tumor samples and their associated metastases identified both prometastatic and metastasis-suppressor miRNAs [15]. These miRNAs modulate the expression of metastasis-associated genes [18, 19], both directly and indirectly, by influencing the epigenetic machinery [20].

Breast cancer is the most frequent carcinoma and the second most common cause of cancer-related mortality in women [21]. In the past decade, it has been repeatedly shown that breast cancer is a heterogeneous condition consisting of at least five [22] but possibly more [23, 24] molecular subtypes. These molecular subtypes (Luminal A, Luminal B, Basal-like, ErbB2+, and Normal-like) are characterized by specific mRNA-expression profiles. Blenkiron and colleagues [14] showed that these specific mRNA-expression profiles are at least partially attributable to differential miRNA expression. Also, Iorio and colleagues [25] identified a global pattern of miRNA deregulation in breast cancer tissue when compared with normal breast tissue, hinting at the importance of miRNA deregulation in the development of breast cancer in general.

As miRNAs appear to be critical regulators of tumor biology, their potential as prognostic and predictive biomarkers has recently been given attention. In addition, their great stability when compared with mRNA molecules, both in blood samples and in formalin-fixed, paraffin-embedded tissue samples, offers a great advantage [26, 27]. Levels of miRNAs do not substantially change when serum or plasma samples are subjected to freeze-thaw cycles, boiling, or maintenance at room temperature [28, 29]. As the bloodstream is easily accessible, blood-borne miRNAs or circulating miRNAs hold the potential to serve as noninvasive biomarkers in oncology.

Recently, Heneghan and colleagues [30] showed that miRNA expression is detectable in whole blood, plasma, and the serum of cancer patients and healthy controls. In addition, miRNA-195 was identified as a potential biomarker for detecting noninvasive and early-stage breast disease [30].

The goal of this study was twofold. First, we aimed to identify patterns of miRNA deregulation in breast cancer. Therefore, we compare miRNA-expression patterns between breast tumor samples classified according to the molecular subtypes and between breast tumor samples and normal breast samples. We hypothesize that such profiles can be informative for breast cancer detection and prognosis and might assist in defining specific targets for future therapy.

Second, we investigated whether the expression levels of miRNAs are measurable in blood samples from patients with breast cancer and healthy volunteers and if such expression profiles are potentially useful for the detection and staging of breast cancer.

Materials and methods

Patients and samples collection

Tumor and blood samples were obtained from patients with breast adenocarcinoma treated in the Breast Clinic of the General Hospital Sint-Augustinus (Antwerp, Belgium). Tissue and serum samples were derived from two entirely independent populations. Each patient gave written informed consent. This study was approved by the Institutional Review Board. Clinicopathologic data are stored in a database in accordance with hospital privacy rules and are summarized in Table 1. All tissue samples were stored in liquid nitrogen within 15 minutes after excision (median delay of 9 minutes). Healthy control tissue was obtained from breast-reductive surgery. None of the control samples showed pathologic changes. In total, 84 tumor samples and eight healthy control samples were included.
Table 1

Clinicopathologic data

Parameter

Group

Tissue (n= 84)

Serum (n= 75)

T status

1

27 (32%)

31 (41%)

 

2

27 (32%)

22 (29%)

 

3

6 (7%)

4 (5%)

 

4

24 (29%)

18 (25%)

N status

0

35 (42%)

28 (37%)

 

1

21 (25%)

15 (20%)

 

2

14 (17%)

10 (13%)

 

3

13 (15%)

9 (12%)

 

4

1 (1%)

13 (18%)

M status

0

70 (83%)

4 (5%)

 

1

14 (17%)

71 (95%)

ER status

Negative

25 (30%)

23 (31%)

 

Positive

59 (70%)

52 (69%)

PR status

Negative

45 (54%)

36 (48%)

 

Positive

39 (46%)

39 (52%)

ErbB2 status

Negative

62 (74%)

49 (65%)

 

Positive

22 (26%)

26 (35%)

Grade

1

9 (11%)

14 (19%)

 

2

32 (38%)

29 (39%)

 

3

43 (51%)

32 (42%)

Stage

I

24 (29%)

19 (25%)

 

II

20 (24%)

14 (19%)

 

III

27 (32%)

22 (29%)

 

IV

13 (15%)

20 (27%)

Disease status

Progressive

29 (35%)

47 (63%)

 

Nonprogressive

55 (65%)

28 (37%)

ErbB2 status is determined by using the Hercep test with confirmation by FISH. Disease status is determined by using the RECIST criteria.

The collection of serum samples was described previously [31]. In brief, samples were prospectively obtained from 75 patients with breast cancer and 20 healthy volunteers. Patients were divided into three groups: four patients with localized breast cancer (group A), 55 patients with metastatic breast cancer receiving treatment (group B), and 16 patients with untreated metastatic breast cancer (group C). The blood samples of patients with metastatic disease were taken during the course of treatment. For all these samples, circulating tumor cells (CTCs) were enumerated by using the CellSearch system (Veridex, Warren, NJ, USA), CK19, and mammaglobin mRNA expression was recorded, the ADNAgen test for detection of CTCs was performed, and levels of total plasma DNA and serum methylated DNA for ESR1, RASSF1A, or APC1 were measured in earlier studies [31, 32]. Disease status was assessed by using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria without knowledge of the patient's CTC or circulating DNA results [33]. Stable disease was measured up to 8 weeks after the initiation of therapy. In addition, we collected blood samples from an additional series of 18 unselected patients to evaluate which blood medium (that is, serum, plasma, platelet-rich plasma, whole blood, or peripheral blood mononuclear cells (PBMCs)) was best suited for extraction of small RNAs (sRNAs).

RNA extraction, cDNA synthesis, and miRNA quantification for tissue samples

After tissue disruption, total RNA was extracted by using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions for total RNA isolation. In brief, the sample was homogenized in a denaturing lysis solution, followed by an acid-phenol:chloroform extraction. Thereafter, the sample was purified on a glass-fiber filter and quantified by using the Nanodrop ND1000 (NanoDrop Technologies, Waltham, MA, USA). Total RNA (100 ng) was converted to cDNA by priming with two pools of stem-looped RT primers (Megaplex RT Primers, Human Pool A & B; Applied Biosystems, Foster City, CA, USA) in combination with the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems), allowing the simultaneous transcription of 377 unique miRNAs and six endogenous controls per primer pool. In brief, 3 μl of total RNA was supplemented with RT primer mix (×10), dNTPs with dTTP (100 mM), Multiscribe Reverse Transcriptase (50 U/μl), RT buffer (×10), MgCl2 (25 mM), and RNase inhibitor (20U/μl) in a total reaction volume of 7.5 μl.

Thermal-cycling conditions were as follows: 40 cycles at 16°C for 2 minutes, 42°C for 1 minute, and 50°C for 1 second, followed by reverse transcriptase inactivation at 85°C for 5 minutes. The Megaplex RT product (2.5 μl) was preamplified by using the TaqMan PreAmp Master Mix (Applied Biosystems) and preamplification primers in a 25-μl PCR reaction. For each pool of stem-looped RT primers in the cDNA reaction, a different pool of PreAmp Primers (Human Pool A & B; Applied Biosystems) was used. Thermal-cycling conditions were as follows: 95°C for 10 minutes, 55°C for 2 minutes, and 75°C for 2 minutes, followed by 12 cycles of 95°C for 15 seconds and 60°C for 4 minutes. MiRNA quantification was performed with the TaqMan Human MicroRNA Array sets A & B (Applied Biosystems), each containing 384 TaqMan miRNA assays. The PreAmp product was diluted fourfold. Each of the eight wells was loaded with 100 μl of PCR reaction mix, containing 50 μl of TaqMan Universal PCR Master Mix, no AmpErase uracil N-glycosylase (UNG) (Applied Biosystems), 1 μl of diluted PreAmp product, and 49 μl of nuclease-free water. Thermal-cycling conditions were as follows: 94.5°C for 10 minutes, followed by 40 cycles at 97°C for 30 seconds and 59.7°C for 1 minute. All PCR reactions were performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems).

To test the efficiency of the miRNA assays, we compared the Ct-values of an undiluted sample with those of a 10-fold diluted sample. To evaluate the linearity of the preamplification, we compared the Ct-values of all miRNAs on both array cards for one sample before and after preamplification. The reproducibility of the arrays was tested by analyzing four samples in duplicate. The robustness of the TaqMan RT-PCR method was investigated by comparing the qRT-PCR miRNA expression profile of 12 samples with their miRNA expression profile obtained by using the nCounter Analysis System (Nanostring Technologies, Seattle, WA, USA). This system is a medium-high throughput gene-expression quantification system with PCR sensitivity that uses a novel digital technology based on direct multiplexed measurement of miRNA expression. Besides a direct quantification, the workflow incorporates only one enzymatic step (ligase step to enable tagging of the miRNAs) instead of three enzymatic steps in the qRT-PCR workflow, thereby substantially reducing the possibility for technical bias. The nCounter experiment was performed in collaboration with the VIB MicroArray Facility (O&N, UZ Gasthuisberg, Leuven, Belgium).

RNA extraction, cDNA synthesis, and miRNA quantification for blood samples

First, we evaluated which blood medium was best suited for the extraction of sRNA molecules. Therefore, plasma, platelet-rich plasma, serum, whole blood, and PBMCs were obtained from 18 patients with breast cancer. Peripheral blood was collected in a 9-ml EDTA tube, from which 3 ml of whole blood was transferred into a cryovial while the remaining blood was centrifuged slowly (150 g, 20 minutes) at 4°C to generate platelet-rich plasma. Plasma and PBMCs were obtained in an 8-ml CPT tube, which was centrifuged (1,650 g, 20 minutes) at room temperature. Plasma and PBMC aliquots were transferred into separate cryovials. Finally, 8 ml blood was collected in serum separator tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and centrifuged (2,000 g, 10 minutes) at room temperature. All samples were stored at -80°C until use.

sRNA was isolated from 200 μl of each medium by using the microRNA Isolation Kit (BioChain Institute Inc, Hayward, CA, USA) according to the manufacturer's instruction for sRNA purification. In brief, after adding lysis buffer to the sample for homogenization, 20 μl of Proteinase K solution (Qiagen, Valencia, CA, USA) was added and incubated for 10 minutes at 75°C to digest the excess of proteins released after addition of the lysis buffer. This was followed by an acid-phenol:chloroform extraction. Small and large RNAs were separated by using a centrifugation step, after which the large RNAs were retained on a glass-fiber filter. The sRNA molecules were recovered from the flow-through by purifying them on a second glass-fiber filter, and their concentration and purity (A260/A280 and A260/A230) was recorded by using the NanoDrop ND1000 (NanoDrop Technologies, Waltham, MA, USA). The concentrations were compared by using a Kruskal-Wallis test with Tukey HSD post hoc testing.

To evaluate circulating miRNA expression in blood samples from 20 healthy volunteers and 75 patients with breast cancer, we isolated total RNA, as described before. Isolated total RNA was reverse transcribed to produce cDNA by using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) by priming with TaqMan MicroRNA Assays (Applied Biosystems) directed at 4 miRNAs identified by comparing tumor tissue with normal breast tissue (vide supra). In addition, miR-16 expression was determined as a normalization factor. In brief, each 15-μl reaction contained 0.15 μl 100 mM dNTPs with dTTP, 1.0 μl Multiscribe Reverse Transcriptase (50 U/μl), 1.50 μl RT Buffer (×10), 0.19 μl RNase Inhibitor (20 U/μl), 4.16 μl nuclease-free water, 5.0 μl total RNA, and 3.0 μl RT primer. Thermal-cycling conditions were 30 minutes at 16°C, 30 minutes at 42°C, and 5 minutes at 85°C. Each 20-μl reaction for the real-time quantitative PCR contained 1.0 μl real-time primer, 1.33 μl product from RT reaction, 10.0 μl TaqMan Universal PCR Master Mix, no AmpErase UNG (Applied Biosystems), and 7.67 μl nuclease-free water. The reactions were performed in duplicate on a 7900HT Fast Real-Time PCR System in the 9600 emulation mode, with conditions of 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. The mirVana miRNA Reference Panel (Ambion, Austin, TX, USA) was included in each PCR plate in a 2,000-fold dilution to correct for between-plate differences.

Statistics and bioinformatics

All subsequent analyses were performed by using BioConductor in R. To reduce technical variation, the miRNA assays with a PCR efficiency outside the range of 2log(10) or 3.32 ± 25% [34] and those with Ct values above 35 in at least 25% of the cases were filtered out. By using efficient and informative miRNA assays only, we calculated the mean difference between the Ct values of one sample before and after preamplification. To avoid technical bias, we excluded miRNA assays with a difference in Ct values before and after preamplification outside the range of the mean value ± 25%. For the final set of miRNAs, we calculated the mean expression level per sample and used this value as a normalization factor to account for differences in input material [35]. Relative miRNA expression levels were calculated by using the ΔCt-method [36] and log2-transformed to obtain a normal distribution. To investigate assay reproducibility, we correlated the expression profiles of the duplicate samples by using the Spearman correlation coefficient.

An additional technical validation was done by performing a pairwise correlation analysis between the miRNA profiles obtained by qRT-PCR and the nCounter Analysis System for the 12 samples analyzed on both platforms. Both correlation analyses were done by using the normalized expression profiles of the 327 common miRNAs only.

Unsupervised hierarchical cluster analysis (UHCA), with the Manhattan distance as similarity metric and Ward clustering as the dendrogram drawing method, was performed to visualize global themes in the expression data. We classified samples according to the miRNA-centroids for molecular subtypes published by Blenkiron et al. [14]. Therefore, we correlated the molecular subtype-specific miRNA-expression profiles of each sample with each of the five miRNA-based expression centroids by using the Spearman correlation coefficient.

The resulting classification was compared with the UHCA result. For 66 samples with available Affymetrix-profiles, we compared the correlation coefficients between the samples grouped according to the SSP (single-sample predictor)-defined molecular subtype classification [37] obtained through mRNA-expression profiling reported in earlier studies [38, 39]. Significance was assessed by using the Mann-Whitney U tests.

Next, we aimed to identify molecular subtype-specific miRNAs. Therefore, we performed a pairwise comparison of the different molecular subtypes, defined through mRNA-expression profiling, by using regression analysis with the limma-package. False Discovery Rate (FDR) correction was performed by using the Benjamini and Hochberg step-up procedure. For each subtype, we crossed the lists of differentially expressed miRNAs resulting from the pairwise comparisons involving the desired subtype in search for common miRNAs.

By using regression analysis, we identified differentially expressed miRNAs between normal and tumor samples. Resulting P values were corrected for false discovery, as described earlier. To investigate global over- or underexpression in normal samples, we calculated the median expression level of the differentially expressed miRNAs per sample. These median expression values were compared by using Mann-Whitney U testing. The top four differentially expressed miRNAs by fold-change were selected for further analysis. For these miRNAs, we identified target mRNAs in at least two of three public databases (PicTar, TargetScan, and Miranda) by using the RmiR-package. These target-gene lists were subjected to Ingenuity Pathway Analysis (IPA) to study the implications of the identified miRNAs in cancer biology.

Expression levels of circulating miRNAs were calculated with miR-16 as normalization factor. Raw Ct values measured in the miRNA Reference Panel were subtracted from the Ct values measured in the samples, yielding a between-plate corrected expression value for each miRNA per 200 μl of serum. The miR-16 normalized expression value was calculated by subtracting the between-plate corrected expression value for miR-16 from the between-plate corrected expression values for the remaining miRNAs (ΔΔCt-method). Relative expression values were calculated by using the 2-ΔΔCt method [36]. To compare the expression data with categoric variables, the Mann-Whitney U test was performed. To compare expression data with continuous variables, Spearman correlation coefficients were calculated.

Results

Technical validation of miRNA profiling in tissue samples

First, we excluded 292 miRNA assays (A panel, 83; B panel, 209) with a Ct value above 35 in at least 25% of the samples, leading to 462 informative miRNAs (A panel, 294; B panel, 168). Before performing the data normalization, we checked the PCR efficiencies of all miRNA assays on the array cards by performing a 10-fold dilution series and subtracting the Ct values of the undiluted sample from the Ct values of the diluted sample. Theoretically, for an efficient PCR reaction, this difference should equal 2log(10) or 3.32. We excluded 23 (A panel, 14; B panel, 9) miRNA assays with PCR-efficiencies outside the range of 3.32 ± 25%. The distribution of the PCR efficiencies and the cut-off values for exclusion are shown in Figure 1A.
https://static-content.springer.com/image/art%3A10.1186%2Fbcr3127/MediaObjects/13058_2011_Article_2965_Fig1_HTML.jpg
Figure 1

The distribution of polymerase chain reaction (PCR) efficiencies, calculated as the differences between the Ct values of undiluted sample and the Ct values of a 10-fold diluted sample. (A) Theoretically, this difference should equal 3.32 or 2log(10). All miRNA assays with a difference in Ct value between 3.32% and 25% were included for further analysis. A blue dashed line indicates the boundaries of the interval; a blue solid line indicates the theoretical expected value of 3.32. To account for differences in preamplification, we compared the Ct values of a sample before and after preamplification. The median difference in Ct value was 8, and all miRNA assays with a difference of 8% ± 25% were included for further analysis. The scatterplot in (B) demonstrates an almost perfect linear relation for those selected miRNAs before and after preamplification. The blue line represents the regression line, for which the equation is given on top of the scatterplot. To evaluate assay reproducibility, we tested four samples in duplicate. The scatterplot in (C) demonstrates the result for one of these samples. The blue line represents the regression line, and the correlation coefficient resulting from the comparison of both profiles is given on top of the scatterplot. Further technical validation of our miRNA-expression data was performed for 12 samples by analyzing their miRNA-expression profile with the nCounter Analysis System and comparing this result with the qRT-PCR-based miRNA-expression profile. The scatterplot in (D) demonstrates the result for one of these samples. The blue line represents the regression line, and the correlation coefficient resulting from the comparison of both profiles is given on top of the scatterplot.

Next we evaluated the linearity of the preamplification by comparing the miRNA-expression profiles of a sample before and after preamplification. This analysis was done for 439 miRNAs that remained after exclusion of noninformative and inefficient miRNA assays. The mean difference between the Ct values before and after preamplification was 8, and miRNA assays with a difference in Ct value outside the range of 8 ± 25% were excluded from further analysis (A panel, 30; B panel, 36). As such, the final data set consisted of 373 miRNAs that were normalized by using the ΔCt method with the median Ct value per sample as normalization factor. The scatterplot comparing the Ct values for those 373 miRNAs before and after preamplification is shown in Figure 1B, and regression analysis demonstrated a significant and linear relation (R 2 = 0.927; P < 0.001).

Next, we investigated the effect of profiling miRNA expression by using two different array cards (A and B) per sample. Therefore, UHCA was performed on the normalized miRNA expression data, and the result is shown in Figure 2. The cluster pattern of the miRNAs, represented by the dendrogram in the Y-axis, reveals that the assays allocated at different array cards are not segregated. In addition, miRNA assays directed at different isoforms of the same miRNA and represented on different array cards cluster on terminal branches in approximately 80% of the cases. These data indicate that variation in miRNA expression related to the incorporation of two separate assays per sample is minor.
https://static-content.springer.com/image/art%3A10.1186%2Fbcr3127/MediaObjects/13058_2011_Article_2965_Fig2_HTML.jpg
Figure 2

Heatmap showing the result of an UHCA (Manhattan distance, Ward linkage) for all 373 miRNAs in all 92 samples. The miRNA-expression data are represented in matrix format, with rows indicating miRNAs and columns indicating samples. Overexpressed miRNAs are color-coded red, and repressed miRNAs are color-coded green. Color saturation indicates the level of overexpression. Six samples clusters could be discerned based on miRNA-expression differences, indicated by alternating blue and grey colors in the dendrogram. Underneath the sample dendrogram, the molecular-subtype classification is indicated (red, Basal-like; orange, ErbB2+; green, Luminal A; blue, Luminal B; gray, Normal-like). The true-normal breast samples are indicated by a darker shade of gray. The colored bar to the side of the heatmap indicates the array card to which the corresponding assay is allocated (red, A; blue, B).

Finally, we evaluated the reproducibility of the miRNA assays. Therefore, we analyzed four samples in duplicate and compared their normalized miRNA expression profiles. A representative scatterplot is show in Figure 1C, and all scatterplots are shown in Additional file 1. Spearman correlation coefficients ranged from 0.98 to 0.99 (all P values < 0.001), indicating good assay reproducibility.

Next, we analyzed the miRNA expression profiles of 12 samples by using the nCounter Analysis System and compared them with the normalized expression data obtained through qRT-PCR. The Spearman correlation coefficients ranged from 0.63 to 0.75 with a median value of 0.72 (all P values < 0.001). Scatterplots for all comparisons are shown in Additional file 2, and a representative scatterplot is provided in Figure 1D.

Overall, our data indicate that technical variation in expression for the panel of 373 miRNAs is minor.

miRNA expression profiling of breast tumor and normal breast samples

With the miRNA centroids for molecular-subtype classification [14], we classified the 84 breast cancer tissue samples and eight normal tissue samples in our data set. 18, 15, 15, 19, and 25 samples were classified as Basal-like, ErbB2+, Luminal A, Luminal B, and Normal-like, respectively. The classification result is shown under the dendrogram in Figure 2. We observed a significant (P < 0.001) agreement between the miRNA-based molecular subtype classification and the clustering pattern of the tissue samples after UHCA. Downstream of the first bifurcation, we observe a cluster composed of 76% of Normal-like samples, which was further divided into two clusters separating the Normal-like tumor samples from the normal breast samples. Further division of the dendrogram yielded a cluster composed of 77% of Basal-like samples and a cluster enriched for Luminal samples (that is, 89% of the samples classify as Luminal A or Luminal B). In addition, 60% of the ErbB2+ samples fell into one sample cluster. Interestingly, downstream of the third bifurcation, we observed a sample cluster not enriched for any of the molecular subtypes (Luminal A, 3; Luminal B, 4; ErbB2+, 3; and Normal-like, 1). Given the hierarchy of the dendrogram, this sample cluster may well represent a novel miRNA-based breast cancer subtype. Overexpressed miRNAs in this sample group are known for their tumor-suppressive roles in (breast) cancer: the miR-200 family (miR-200a, miR-200b, miR-200c, and miR-141), the let-7 family (let-7a, let-7f, and let-7g), and NFκB-regulating miRNAs (miR-146a and miR-155).

For 66 of 92 samples, Affymetrix mRNA expression profiles were obtained in previous studies [38, 39]. Classification of these samples according to the SSP-algorithm yielded an agreement of 66% with the classification according to the miRNA centroids. Subtype-specific correlation coefficients were compared between the SSP-defined molecular subtypes, and results are shown in Figure 3. For all comparisons, the subtype-specific correlation coefficients obtained by using the miRNA-centroids were significantly elevated in the group of samples classified in the corresponding subtype by using mRNA data (all P values < 0.05). When dichotomizing the Spearman correlation coefficients per subtype relative to 0, we observed an average classification error rate of 36%, with the highest and lowest classification error rates observed for the Luminal B and ErbB2+ samples (44% and 27%), respectively.
https://static-content.springer.com/image/art%3A10.1186%2Fbcr3127/MediaObjects/13058_2011_Article_2965_Fig3_HTML.jpg
Figure 3

Comparison of the mRNA-based molecular subtype classification by using the SSP method with the miRNA-based classification by using the expression centroids reported by Blenkiron and colleagues. This analysis was performed only for those samples for which Affymetrix mRNA-expression profiles are available (N = 66). The SSP-classification is provided in the X-axis (B, Basal; E, ErbB2+; LA, Luminal A; LB, Luminal B; N, Normal-like; and R, Rest). The Spearman correlation coefficients resulting from the miRNA-based molecular subtype classification are indicated in the Y-axis. For each miRNA-based molecular subtype-specific centroid and each sample in our data set, the Spearman correlation coefficients were determined. The molecular subtype-specific correlation coefficients were statistically compared between samples belonging to and not belonging to the SSP-defined molecular subtype of interest. P values are indicated under the corresponding boxplots.

To identify subtype-specific miRNAs, we performed pairwise comparisons between tumor samples grouped by the SSP-defined molecular subtypes. The results are summarized in Table 2. At a P-value cut-off level of 0.01 (maximal FDR of 15%), we identified 16, 0, 2, 3, and 40 miRNAs specific for the Basal-like, ErbB2+, Luminal A, Luminal B, and Normal-like subtypes, respectively. Comparison of these results with the expression data published by Blenkiron and colleagues [14] revealed remarkably similar expression patterns for several key miRNAs. For example, miR-135b and miR-106a are upregulated in Basal-like breast cancers in both studies. Also, miR-100 and miR-145 show comparable expression patterns in both studies, with elevated expression in the Normal-like and Luminal samples. Detailed results are provided in Additional file 3.
Table 2

Identification of subtype-specific miRNAs

Subtype

Comparator

Number

Common

Basal-like

ErbB2+

26

hsa-miR-135b#, hsa-miR-135b, hsa-miR-934, hsa-miR-577, hsa-miR-501-5p, hsa-miR18a#, hsa-miR-92a, hsa-miR-106a, hsa-miR-17, hsa-miR-18b, hsa-miR-18a, hsa-miR-20a, hsa-miR-17#, hsa-miR-15b#, hsa-miR-19a, hsa-miR-500

 

Luminal A

53

 
 

Luminal B

33

 
 

Normal-like

90

 

ErbB2+

Basal-like

26

-

 

Luminal A

25

 
 

Luminal B

14

 
 

Normal-like

107

 

Luminal A

Basal-like

53

hsa-miR-148a, hsa-miR-219-5p

 

ErbB2+

25

 
 

Luminal B

15

 
 

Normal-like

106

 

Luminal B

Basal-like

33

hsa-miR-30d#, hsa-miR-30d, hsa-miR-342-3p

 

ErbB2+

14

 
 

Luminal A

15

 
 

Normal-like

109

 

Normal-like

Basal-like

90

hsa-miR-136#, hsa-miR-497, hsa-miR-139-5p, hsa-miR-99a#, hsa-miR-145#, hsa-miR-195, hsa-miR-143, hsa-miR-145, hsa-miR-335, hsa-miR-125b-2#, hsa-miR-139-3p, hsa-miR-7-2#, hsa-miR-216b, hsa-miR-487b, hsa-miR-100, hsa-miR-410, hsa-miR-204, hsa-miR-376a, hsa-miR-99a, hsa-miR-337-3p, hsa-miR-27a#, hsa-miR-411, hsa-miR-656, hsa-miR-495, hsa-miR-551b#, hsa-miR-770-5p, hsa-let-7b#, hsa-miR-378, hsa-miR-215, hsa-miR-127-3p, hsa-let-7c#, hsa-miR-379, hsa-miR-422a, hsa-miR432, hsa-miR-299-5p, hsa-miR-494, hsa-miR-378, hsa-miR-511, hsa-miR-23a#, hsa-miR-452

 

ErbB2+

107

 
 

Luminal A

106

 
 

Luminal B

109

 

P values, < 0.01; maximal false discovery rate, 15%.

Finally, we compared the miRNA expression profiles of tumor samples with the normal breast samples obtained after breast-reductive surgery. As reported earlier, the clustering pattern of the tissue samples (Figure 2) suggests major differences in miRNA expression between the tumor samples and normal breast samples. We identified 59 differentially expressed miRNAs at an FDR less than 1%. The median expression value of these miRNA per sample was significantly higher in normal breast samples (Normal, 1.542; Tumor, 0.024; P < 0.001). Data are presented in boxplot format in Figure 4A. The top four miRNAs by fold-change (miR-299-5p, miR-215, miR-411, and miR-452) were selected as potential biomarkers for breast cancer detection (Figure 4B through 4E). With the RmiR-package, we identified 611, 715, 575, and 1,863 mRNA targets for the set of selected miRNAs, respectively, which were analyzed by using Ingenuity Pathway Analysis. For each miRNA, the five most relevant networks with their most strongly enriched molecular and cellular functions (P < 0.001) are listed in Table 3. Comparative analysis of enrichment patterns demonstrated that all miRNAs were involved in the regulation of global oncogenic processes like cell proliferation, cell death, and cellular movement.
https://static-content.springer.com/image/art%3A10.1186%2Fbcr3127/MediaObjects/13058_2011_Article_2965_Fig4_HTML.jpg
Figure 4

Comparison of normal breast samples with tumor samples. We identified 59 differentially expressed miRNAs between tumor samples and normal breast samples. The median expression of these miRNAs is significantly elevated in normal breast samples, as illustrated by the boxplot (A). The top four miRNAs (miR-215, miR-299-5p, miR-411, and miR-452) with the greatest difference between normal breast samples and breast tumor samples by fold change are depicted in panels B through E. The corresponding false discovery rate is provided in top of each boxplot. All miRNAs are significantly overexpressed in normal breast samples.

Table 3

Biologic and cellular functions of miR-215, miR-299-5p, miR-411, and miR-452

miRNA

Network ID

Score

Number of genes

Top associated functions

miR-215

1

37

28

Tissue morphology, cell death, drug metabolism

 

2

20

19

Developmental disorder, gene expression, genetic disorder

 

3

20

19

Cellular movement, immune cell trafficking, skeletal and muscular system development and function

 

4

14

15

RNA damage and repair, cell death, molecular transport

 

5

13

14

Genetic disorder, cellular assembly and organization, cellular function and maintenance

miR-299-5p

1

35

29

Cell-to-cell signaling and interaction, cellular growth and proliferation, tumor morphology

 

2

24

23

Gene expression, cellular movement, lipid metabolism

 

3

13

16

Cellular assembly and organization, DNA replication, recombination, and repair, gene expression

 

4

13

16

Cell morphology, cellular development, protein synthesis

 

5

11

14

Cell death, renal necrosis/cell death, cellular compromise

miR-411

1

33

26

Cell death, cell-to-cell signaling and interaction, cell-mediated immune response

 

2

27

23

Cardiovascular system development and function, organ development, organismal development

 

3

17

17

Gene expression, protein synthesis, antimicrobial response

 

4

14

15

Cell death, cellular growth and proliferation, cellular assembly and organization

 

5

11

13

Inflammatory response, dermatologic diseases and conditions, inflammatory disease

miR-452

1

31

32

Gene expression, cellular movement, cell death

 

2

27

30

Cell-to-cell signaling and interaction, connective tissue development and function, cell morphology

 

3

25

29

Cellular growth and proliferation, inflammatory response, cell death

 

4

25

29

Cellular development, gene expression, nervous system development and function

 

5

25

29

Cellular growth and proliferation, cardiovascular disease, tissue morphology

Circulating miRNA expression

To evaluate which blood medium was best suited for investigating miRNA expression, we extracted sRNA molecules from serum, plasma, platelet-rich plasma, whole blood, and PBMCs. A significant increase in sRNA concentration was observed only when comparing the results obtained in whole blood with the results obtained in other media (Kruskal-Wallis, P < 0.001; Tukey HSD post hoc, all P values < 0.001). Results are shown in Additional file 4. As our aim was to measure circulating, tumor-specific miRNA expression, we decided not to perform subsequent analyses on platelet-rich plasma, whole blood, or PBMCs because of the possible contamination of host-specific miRNA expression. Given a slight, not significant, increase in sRNA concentration in serum when compared with plasma (5.3 μg/ml versus 4.2 μg/ml), in addition to a more-consistent sRNA yield in serum (CVserum, 50.4%; CVplasma, 94.5%), we decided to use serum to evaluate circulating miRNA expression.

The expression of four miRNAs (miR-299-5p, miR-215, miR-411, and miR-452) with the greatest fold-change, when comparing normal breast tissue with breast tumor samples, was analyzed in serum samples from 75 patients with breast cancer and 20 healthy volunteers. We observed higher expression values for all investigated miRNAs, except for miR-452, in serum from healthy volunteers. Significant (P < 0.05) values were obtained for miR-299-5p and miR-411, whereas trends (P < 0.10) were observed for miR-215 and miR-452. Results are shown in Figure 5.
https://static-content.springer.com/image/art%3A10.1186%2Fbcr3127/MediaObjects/13058_2011_Article_2965_Fig5_HTML.jpg
Figure 5

Comparison of the expression profiles of miR-215, miR-299-5p, miR-411, and miR-452 between serum samples from patients with breast cancer and serum samples from healthy volunteers (A through D). The boxplots on panels E through H represent the comparison of the expression profiles of the same miRNAs between serum samples from healthy volunteers and from patients with metastatic breast cancer receiving and not receiving treatment. The P values indicating the significance of the difference are indicated on top of the boxplots.

We next compared the expression levels of miR-215, miR-299-5p, miR-411, and miR-452 in serum from patients with metastatic breast cancer receiving treatment (group B), patients with untreated metastatic breast cancer (group C), and healthy volunteers. The group of patients with localized breast cancer was not included in this analysis because of low sample size (n = 4). Results are shown in Figure 5. Kruskal-Wallis testing revealed significant (P < 0.05) between-group differences for all miRNAs, except miR-452. Tukey HSD post hoc testing revealed that the lowest expression values were observed in patients with metastatic breast cancer, whereas expression levels returned to normal with treatment.

Finally, we compared the expression levels of the circulating miRNAs with clinicopathologic variables, response to treatment evaluated by the RECIST-criteria, presence of circulating tumor markers, and the presence of circulating methylated markers. These analyses were done for all samples except those derived from healthy volunteers. Results are shown in Table 4. Overall, few significant associations were observed. The expression levels for three of four miRNAs (miR-215, miR-299-5p, and miR-411) show a negative association with patient age at diagnosis (all P values < 0.100). Interestingly, all miRNAs have higher expression levels in serum from patients with progressive disease under treatment and for two of four miRNAs (miR-215 and miR-411); these differences were significant (P < 0.050). No associations between circulating miRNA expression and the presence of CTCs were observed. For miR-215 and miR-452, we observed positive associations (P < 0.05) between their expression levels in serum and the number of methylated genes (any combination of ESR1, APC, and RASSF1A) detected in plasma.
Table 4

Associations between circulating miRNA expression and clinicopathologic variables

Group

Variable

Test

MIR-215

MIR-299-5p

MIR-411

MIR-452

   

Result

P-value

Result

P-value

Result

P-value

Result

P-value

Clinicopathologic

Age

Spearman correlation

R = -0.184

P = 0.113

R = -0.455

P < 0.001

R = -0.362

P = 0.001

R = -0.052

P = 0.657

 

ERa

Mann-Whitney U test

T = -1.059

P = 0.295

T = 0.658

P = 0.516

T = 0.305

P = 0.763

T = 1.194

P = 0.244

 

PRa

Mann-Whitney U test

T = -0.672

P = 0.504

T = -0.193

P = 0.848

T = -0.645

P = 0.521

T = 1.519

P = 0.136

 

HRa

Mann-Whitney U test

T = -1.233

P = 0.225

T = 0.632

P = 0.534

T = 0.299

P = 0.767

T = 1.015

P = 0.321

 

ERBB2a

Mann-Whitney U test

T = 0.051

P = 0.960

T = -1.237

P = 0.222

T = -1.594

P = 0.120

T = -0.841

P = 0.406

 

TNBCa

Mann-Whitney U test

T = -0.399

P = 0.699

T = -0.310

P = 0.765

T = -0.365

P = 0.725

T = 0.281

P = 0.785

 

P53a

Mann-Whitney U test

T = 0.256

P = 0.800

T = 1.041

P = 0.304

T = 1.617

P = 0.113

T = -0.953

P = 0.347

RECIST

Progressive diseasea

Mann-Whitney U test

T = -2.404

P = 0.019

T = -0.998

P = 0.322

T = -2.488

P = 0.016

T = -0.399

P = 0.691

Circulating markers

Number CTCs

Spearman correlation

R = 0.056

P = 0.635

R = -0.026

P = 0.826

R = 0.053

P = 0.655

R = -0.094

P = 0.424

 

ADNAGena

Mann-Whitney U test

T = -0.534

P = 0.596

T = 1.789

P = 0.078

T = 0.782

P = 0.437

T = -2.144

P = 0.041

 

Mammaglobin expression

Spearman correlation

R = 0.047

P = 0.697

R = 0.005

P = 0.969

R = 0.086

P = 0.474

R = -0.107

P = 0.374

 

Cytokeratin 19 expression

Spearman correlation

R = 0.191

P = 0.110

R = -0.099

P = 0.409

R = -0.010

P = 0.933

R = 0.004

P = 0.968

 

Plasma DNA concentration

Spearman correlation

R = 0.200

P = 0.085

R = -0.100

P = 0.392

R = -0.043

P = 0.712

R = 0.085

P = 0.467

Methylated markers

RASSF1A

Spearman correlation

R = -0.129

P = 0.271

R = -0.198

P = 0.089

R = -0.189

P = 0.104

R = 0.025

P = 0.829

 

APC

Spearman correlation

R = -0.144

P = 0.217

R = -0.134

P = 0.253

R = -0.114

P = 0.332

R = -0.010

P = 0.930

 

ESR1

Spearman correlation

R = 0.148

P = 0.205

R = 0.001

P = 0.997

R = 0.086

P = 0.461

R = 0.252

P = 0.029

 

Number methylated genes

Spearman correlation

R = 0.250

P = 0.031

R = -0.159

P = 0.172

R = -0.039

P = 0.740

R = 0.262

P = 0.023

 

Methylation statusa

Mann-Whitney U test

T = -1.583

P = 0.118

T = 1.456

P = 0.152

T = 0.538

P = 0.593

T = -1.270

P = 0.208

aA negative T-value indicates a higher expression in the "positive" group.

Discussion

We attempted to identify a panel of deregulated miRNAs in breast cancer and investigated their potential as biomarkers for the detection and staging of breast cancer by using blood-based testing. Before analyzing the miRNA-expression data, we first evaluated the performance of the PCR technology used throughout this study. To reduce the technical variation in our data set, we included only informative miRNAs assays (Ct values smaller than 35 in at least 25% of the cases) with similar PCR efficiencies and similar differences in Ct values before and after preamplification. The boundaries for PCR efficiency were defined as described in earlier studies [34], and the boundaries for preamplification efficiency were set alike. The expression data recorded by the final set of 373 selected miRNAs proved to be reproducible, and no between-array card difference was observed. Moreover, we noticed an above-moderate agreement between the qRT-PCR-based miRNA profiles of 12 samples with the miRNA profiles measured by using the nCounter Analysis System.

This is important for two reasons. First, the nCounter Analysis System incorporates only one enzymatic step (that is, a ligase treatment for attachment of the reporter tags) in its workflow and is therefore less prone to technical bias than is the PCR-based protocol that incorporates three enzymatic steps.

A second reason for comparing the miRNA expression profiles by using alternative profiling techniques is related to the fact that good normalization procedures for miRNA expression data are currently still lacking. The qRT-PCR-based miRNA-expression data in this study were normalized relative to the mean expression value of all miRNAs per sample, as proposed by Mestdagh et al. [35]. However, we think that this normalization procedure might have a major drawback because of the role of DICER1, a miRNA-preprocessing enzyme, in breast cancer. Recent reports have shown that the expression of DICER1 is different across the different molecular subtypes [14, 4042]. As DICER1 is involved in cleaving the precursor miRNAs into mature miRNAs, variation in DICER1 expression might result in altered turnover rates of the precursor miRNAs and, hence, higher concentrations of mature miRNAs in those tumor samples with higher DICER1 expression. Therefore, we reason that the mean miRNA-expression levels can vary depending on DICER1 expression and that normalization relative to the mean miRNA-expression level might obscure between-sample differences, particularly in breast cancer. The alternative approach would be to use the reference miRNAs provided on the array cards or miR-16, which is often suggested as reference miRNA. However, the CVs for these reference miRNAs were about threefold higher than the CV of the mean miRNA expression level per sample. In addition, about 20% of the miRNA assays on both array cards yielded more-robust expression data (data not shown).

Therefore, in spite of our previously raised concerns, we decided to normalize our expression data relative to the mean Ct value per sample and compare the results with the data obtained by using nCounter Analysis System, which uses a panel of five mRNA assays (RPLPO, RPL19, ACTB, B2M, and GAPDH) for data normalization. The above-moderate agreement between the miRNA-expression data obtained by using both profiling techniques lends credit to the biologic validity of our qRT-PCR-based miRNA-expression profiles.

Further evidence that the applied normalization procedure did not obscure molecular subtype-specific differences is derived from the UHCA, which showed that the molecular subtypes govern global themes in our miRNA expression data set. Also, the miRNA-based molecular subtype classification is in agreement with the classification resulting from the application of a more-validated algorithm on mRNA data (SSP) [37]. For example, the comparison of the miRNA-based expression profile of SSP-defined Basal-like breast tumors with the miRNA-based expression centroid for Basal-like breast cancer results in more-elevated Spearman correlation coefficients than when compared with the results obtained for non-Basal-like breast tumor samples. Although the classification error rate was substantial, we must keep in mind that the miRNA-based expression centroids reported by Blenkiron and colleagues [14] are based on a limited series of samples. Therefore, it is arguable that the expression centroids are not very stable, which affects the classification accuracy. When performing a supervised analysis, we were able to identify sets of specific miRNAs for each molecular subtype, except for the ErbB2+ breast tumor samples. Overall, our results are in line with previously reported data [14, 4345], except for the results with respect to the ErbB2+ subtype, for which an miRNA signature has been defined in the past [45]. Of note is the concordant overexpression of miRNAs belonging to the polycistronic miR-17-92 cluster (miR-17, miR-18a, miR-19a, miR-20a, and miR-92) and its paralogs (miR-18b and miR-106a) in Basal-like breast tumors. The miR-17-92 cluster is known to downregulate ERα in a MYC-dependent manner and inhibits the protein translation of AIB1, an ERα transcriptional coactivator [46]. Also, the miR-17-92 cluster is known to regulate cell migration, invasion, and metastasis in breast cancer by regulating ROCK [47] and the HBP1/β-catenin pathway [48].

Although the sample-clustering pattern based on the expression of 373 miRNAs demonstrated that the global themes in our expression data set are related to the presence of the classic molecular subtypes in breast cancer, we did identify one sample cluster without any connection to the classic molecular subtypes. This sample cluster originated early in the dendrogram, indicative of a specific miRNA-expression profile. Indeed, the heatmap did reveal an miRNA cluster, including members of the miR-200 family, members of the let-7 family, and NFκB-regulating miRNAs [49], that is overexpressed in this group of tumor samples, at a level exceeding the expression level observed in the Luminal-like sample cluster. The latter observation is at least remarkable, as all these miRNA families are known to inhibit stem cell-specific pathways, epithelial-to-mesenchymal transition, cell proliferation, and other global oncogenic processes [16, 5053]. Hence, their overexpression would induce a more-differentiated, less-proliferative, less-mesenchymal, and less-migratory/invasive cell phenotype. The presence of this tumor sample cluster with its particular molecular characteristics warrants further investigation. When focusing on the Normal-like samples, a clear and distinct miRNA profile was observed. In addition, the true normal breast samples constituted a coherent group inside the cluster of the Normal-like samples, suggesting vast differences in miRNA expression between tumor samples and normal breast samples. Indeed, supervised analysis revealed high numbers of differentially expressed miRNAs with nominal (uncorrected) P values less than 0.05.

The huge difference in miRNA expression between normal and tumor samples underlines the important role of miRNA deregulation in the development of breast cancer. After correction for false discovery, we observed that the majority of the differentially expressed miRNAs have attenuated expression levels in the tumor samples. The global repression of miRNAs in cancerous tissue relative to normal tissue has been reported previously and suggests that most miRNAs have a tumor-suppressive function [13]. This view is corroborated by reports on the cellular functions of the top four (miR-215, miR-299-5p, miR-411, and miR-452) differentially expressed miRNAs by fold-change. Song et al. [54] demonstrated that miR-215 overexpression in a colon cancer cell line reduced the proliferation rate and led to improved cell-cycle control, probably due to an increased expression of the cell-cycle control genes p53 and p21. Duan et al. [55] showed that miR-299-5p expression increased downstream of the tumor suppressor PRDM5 in HEK293 cells. In contrast, Fang et al. [56] showed that SOX2, a gene with tumor-promoting activity involved in cell proliferation and colony formation of LN229 glioblastoma multiforme cells, represses miR-452. The evidence for a role of miR-411 as tumor suppressor is less clear, but this miRNA is located at the 14q32.31 locus, which is known to harbor many tumor-suppressive miRNAs [57]. The biologic processes regulated by miR-215, miR-299-5p, miR-411, and miR-452, identified through the analysis of their respective target-gene lists, are in line with their role in maintaining cellular homeostasis.

Because of the marked overexpression of miR-215, miR-299-5p, miR-411, and miR-452 in normal breast samples, in addition to the fact that miRNAs have a proven stability in blood samples [29], we hypothesized that this panel of miRNAs might be suitable for the detection of breast cancer by using blood-borne testing. The reason for using serum samples for this purpose is twofold. First, we argued that miRNA-expression profiles in whole blood, platelet-rich plasma, and PBMCs would be dominated by host miRNA expression, and therefore would be less suitable for the detection of tumor-specific miRNA expression. Conversely, reports have shown that miRNA expression is also detectable in serum and plasma samples from healthy donors [58]. Second, we noticed a slightly higher and more consistent sRNA yield in serum as compared with plasma. When evaluating the relative expression profiles of miR-215, miR-299-5p, miR-411, and miR-452 in serum samples from patients with breast cancer and healthy volunteers, we recorded comparable expression profiles in tissue and blood samples, except for miR-452. Of note, when comparing absolute CT values, the expression differences between samples from patients with breast cancer and healthy volunteers were maintained, however, at a higher fold-change level. In addition, we observed that the reduction of miRNA expression was particularly obvious in serum samples from patients with untreated metastatic breast cancer, whereas the expression profiles "normalized" with treatment.

No associations between blood-borne miRNA expression in serum samples from patients with breast cancer and the classical clinicopathologic variables were observed, except for the patient's age at diagnosis. However, this should not be surprising, as our miRNA panel was not selected to make this distinction. Of note is the lack of associations between circulating miRNA expression and the presence of CTCs, measured by three alternative techniques. This observation suggests that recorded serum miRNA profiles are not CTC derived and that the mechanisms responsible for the release of miRNAs in the circulation are unrelated to the extravasation of tumor cells. Indeed, several reports have suggested that miRNAs are selectively released in the bloodstream by tumor cells either via exosomes or attached to lipoprotein complexes or within a functional RISC complex [5963]. These mechanisms of secretion offer an explanation for the marked stability of miRNAs in the blood stream, due to shielding of the associated miRNAs from RNAse-activity. In addition, miRNAs secreted as such are functionally active and have been found to regulate gene expression in target cells, thereby providing alternative ways of cell-cell communication. This opens the possibility that miRNAs, secreted by tumor cells, evoke a response in host cells altering their expression profile, which explains how subtle differences in tumor-specific expression are measurable in a background of nontumorigenic expression. More specific in the context of our results, one could envision that tumor-driving miRNAs, secreted by tumor cells, affect the expression profile of host cells, which is reflected in the serum profile of breast cancer patients and explains the observed decrease in miRNA expression.

Conclusions

The present data provide a technologically validated framework to elaborate on the study of miRNA-deregulation in the development of breast cancer. We potentially identified a novel subgroup of breast tumors with elevated expression of tumor-suppressive miRNAs, and we showed that miRNAs can be used as blood-borne biomarkers for detection and staging of breast cancer. The identification of several molecular subtype-specific miRNAs in this study also suggests that blood tests directed at the molecular subtypes can be developed in the future. However, to do so, a larger repository of molecular subtype-specific miRNA expression is required.

Notes

Abbreviations

CTC: 

circulating tumor cell

FDR: 

false discovery rate

miRNA: 

microRNA

PBMC: 

peripheral blood mononuclear cell

RECIST: 

response-evaluation criteria in solid tumors

RISC: 

RNA-induced silencing complex

sRNA: 

small RNA

SSP: 

single sample predictor

UHCA: 

unsupervised hierarchical cluster analysis.

Declarations

Authors’ Affiliations

(1)
Department of Oncology, University Hospitals Leuven and Catholic University Leuven
(2)
Translational Cancer Research Unit, GZA Hospitals St-Augustinus
(3)
Radboud University Nijmegen Medical Center
(4)
Department of Medical Oncology, University Hospital Antwerp

References

  1. Ambros V: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003, 113: 673-676. 10.1016/S0092-8674(03)00428-8.View ArticleGoogle Scholar
  2. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5.View ArticleGoogle Scholar
  3. He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004, 5: 522-531. 10.1038/nrg1379.View ArticleGoogle Scholar
  4. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005, 433: 769-773. 10.1038/nature03315.View ArticleGoogle Scholar
  5. Sevignani C, Calin GA, Siracusa LD, Croce CM: Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006, 17: 189-202. 10.1007/s00335-005-0066-3.View ArticleGoogle Scholar
  6. Zamore PD, Haley B: Ribo-gnome: the big world of small RNAs. Science. 2005, 309: 1519-1524. 10.1126/science.1111444.View ArticleGoogle Scholar
  7. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005, 120: 15-20. 10.1016/j.cell.2004.12.035.View ArticleGoogle Scholar
  8. Erson AE, Petty EM: MicroRNAs in development and disease. Clin Genet. 2008, 74: 296-306. 10.1111/j.1399-0004.2008.01076.x.View ArticleGoogle Scholar
  9. Cheng AM, Byrom MW, Shelton J, Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33: 1290-1297. 10.1093/nar/gki200.View ArticleGoogle Scholar
  10. Xu P, Guo M, Hay BA: MicroRNAs and the regulation of cell death. Trends Genet. 2004, 20: 617-624. 10.1016/j.tig.2004.09.010.View ArticleGoogle Scholar
  11. Karp X, Ambros V: Developmental biology: encountering microRNAs in cell fate signaling. Science. 2005, 310: 1288-1289. 10.1126/science.1121566.View ArticleGoogle Scholar
  12. Pillai RS: MicroRNA function: multiple mechanisms for a tiny RNA?. RNA. 2005, 11: 1753-1761. 10.1261/rna.2248605.View ArticleGoogle Scholar
  13. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-838. 10.1038/nature03702.View ArticleGoogle Scholar
  14. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin S-F, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007, 8: R214-10.1186/gb-2007-8-10-r214.View ArticleGoogle Scholar
  15. Baffa R, Fassan M, Volinia S, O'Hara B, Liu C, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A: MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009, 219: 214-221. 10.1002/path.2586.View ArticleGoogle Scholar
  16. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006, 103: 2257-2261. 10.1073/pnas.0510565103.View ArticleGoogle Scholar
  17. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S, Piccolo S: A microRNA targeting dicer for metastasis control. Cell. 2010, 141: 1195-1207. 10.1016/j.cell.2010.05.017.View ArticleGoogle Scholar
  18. Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007, 449: 682-688. 10.1038/nature06174.View ArticleGoogle Scholar
  19. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA family. Cell. 2005, 120: 635-647. 10.1016/j.cell.2005.01.014.View ArticleGoogle Scholar
  20. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 2007, 104: 15805-15810. 10.1073/pnas.0707628104.View ArticleGoogle Scholar
  21. Bombonati A, Sgroi DC: The molecular pathology of breast cancer progression. J Pathol. 2011, 223: 307-317.View ArticleGoogle Scholar
  22. Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.View ArticleGoogle Scholar
  23. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12: R68-10.1186/bcr2635.View ArticleGoogle Scholar
  24. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR: A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010, 107: 6994-6999. 10.1073/pnas.0912708107.View ArticleGoogle Scholar
  25. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce C: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65: 7065-7070. 10.1158/0008-5472.CAN-05-1783.View ArticleGoogle Scholar
  26. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007, 13: 1668-1674. 10.1261/rna.642907.View ArticleGoogle Scholar
  27. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, Guenther SM, O'Leary JJ, Sheils O: Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007, 7: 1-6. 10.1186/1472-6750-7-1.View ArticleGoogle Scholar
  28. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A: Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008, 3: e3148-10.1371/journal.pone.0003148.View ArticleGoogle Scholar
  29. Mitchell PS, Parkin RK, Kroh EM, Frits BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KCO, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008, 105: 10513-10518. 10.1073/pnas.0804549105.View ArticleGoogle Scholar
  30. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010, 251: 499-505. 10.1097/SLA.0b013e3181cc939f.View ArticleGoogle Scholar
  31. Van der Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer. 2009, 100: 1277-1286. 10.1038/sj.bjc.6605013.View ArticleGoogle Scholar
  32. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prové A, Maes H, Huget P, van Dam P, Vermeulen PB, Dirix LY: Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer. 2010, 102: 276-284. 10.1038/sj.bjc.6605472.View ArticleGoogle Scholar
  33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093/jnci/92.3.205.View ArticleGoogle Scholar
  34. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramírez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW: mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res. 2011, 17: 3600-3618. 10.1158/1078-0432.CCR-11-0255.View ArticleGoogle Scholar
  35. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J: A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009, 10: R64-10.1186/gb-2009-10-6-r64.View ArticleGoogle Scholar
  36. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticleGoogle Scholar
  37. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009, 27: 1160-1167. 10.1200/JCO.2008.18.1370.View ArticleGoogle Scholar
  38. Van Laere S, Van der Auwera I, Van den Eynden G, Van Hummelen P, van Dam P, Van Marck E, Vermeulen PB, Dirix L: Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer. 2007, 97: 1165-1174. 10.1038/sj.bjc.6603967.View ArticleGoogle Scholar
  39. Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, Pauwels P, Vermeulen PB, Dirix LY, Van Laere SJ: Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS ONE. 2010, 5: e12616-10.1371/journal.pone.0012616.View ArticleGoogle Scholar
  40. Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ: Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer. 2010, 103: 532-541. 10.1038/sj.bjc.6605787.View ArticleGoogle Scholar
  41. Cheng C, Fu X, Alves P, Gerstein M: mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol. 2009, 10: R90-10.1186/gb-2009-10-9-r90.View ArticleGoogle Scholar
  42. Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, Jones RL, Reis-Filho JS: Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011, 47: 138-150. 10.1016/j.ejca.2010.08.007.View ArticleGoogle Scholar
  43. Janssen EAM, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, Søiland H, Baak JP: Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol. 2010, 23: 1567-1576. 10.1038/modpathol.2010.177.View ArticleGoogle Scholar
  44. Bockmeyer CL, Christgen M, Müller M, Fischer S, Ahrens P, Länger F, Kreipe H, Lehmann U: MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat. 2011,Google Scholar
  45. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009, 11: R27-10.1186/bcr2257.View ArticleGoogle Scholar
  46. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P, Barton G, Jiao LR, Wait R, Waxman J, Hannon GJ, Stebbing J: The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA. 2009, 106: 15732-15737. 10.1073/pnas.0906947106.View ArticleGoogle Scholar
  47. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M: Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res. 2009, 69: 8742-8751. 10.1158/0008-5472.CAN-09-1541.View ArticleGoogle Scholar
  48. Li H, Bian C, Liao L, Li J, Zhao RC: miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat. 2011, 126: 565-575. 10.1007/s10549-010-0954-4.View ArticleGoogle Scholar
  49. Ma X, Becker Buscaglia LE, Barker JR, Li Y: MicroRNAs in NF-kappaB signaling. J Mol Cell Biol. 2011, 3: 159-166. 10.1093/jmcb/mjr007.View ArticleGoogle Scholar
  50. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM: Breast Cancer Special Feature: Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA. 2011,Google Scholar
  51. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, Lindeman GJ, Shannon MF, Drew PA, Khew-Goodall Y, Goodall GJ: An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011, 22: 1686-1698. 10.1091/mbc.E11-02-0103.View ArticleGoogle Scholar
  52. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature. 2008, 10: 593-601.Google Scholar
  53. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007, 131: 1109-1123. 10.1016/j.cell.2007.10.054.View ArticleGoogle Scholar
  54. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J: Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010, 9: 96-10.1186/1476-4598-9-96.View ArticleGoogle Scholar
  55. Duan Z, Person RE, Lee H-H, Huang S, Donadieu J, Badolato R, Grimes HL, Papayannopoulou T, Horwitz MS: Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5. Mol Cell Biol. 2007, 27: 6889-6902. 10.1128/MCB.00762-07.View ArticleGoogle Scholar
  56. Fang X, Yoon J-G, Li L, Yu W, Shao J, Hua D, Zheng S, Hood L, Goodlett DR, Foltz G, Lin B: The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics. 2011, 12: 11-10.1186/1471-2164-12-11.View ArticleGoogle Scholar
  57. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, Cohen MA, Zelikovitch B, Shoshan Y, Spektor S, Reubinoff BE, Felig Y, Gerlitz O, Ben-Hur T, Smith Y, Siegal T: Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol. 2010, 12: 422-433.View ArticleGoogle Scholar
  58. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB: Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE. 2008, 3: e3694-10.1371/journal.pone.0003694.View ArticleGoogle Scholar
  59. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011, 108: 5003-5008. 10.1073/pnas.1019055108.View ArticleGoogle Scholar
  60. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011, 13: 423-433. 10.1038/ncb2210.View ArticleGoogle Scholar
  61. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007, 9: 654-659. 10.1038/ncb1596.View ArticleGoogle Scholar
  62. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C: Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010, 123: 1603-1611. 10.1242/jcs.064386.View ArticleGoogle Scholar
  63. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM: Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE. 2010, 5: e13515-10.1371/journal.pone.0013515.View ArticleGoogle Scholar

Copyright

© van Schooneveld et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.